Clinical trial · Interventional
Comparison of Multiparametric Prostate MRI and Ga-68 PSMA PET Imaging in Prostate Cancer Staging
NCT05427864CI-TRIAL-00059334unknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
In this study, it is aimed to compare the lesion location, lesion size, local and distant metastases detection rates of Ga68 PSMA PET and Multiparametric Prostate MR imaging tests used in staging in patients diagnosed with prostate cancer. The pathologies of the patients who were decided to undergo radical prostatectomy as a treatment will also be compared with the staging tests.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
| Prostate Cancer Stage | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Multiparametric Prostate MRI | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (5)
- measure
- Lesion location
- timeFrame
- Between prostate biopsy and curative treatment decision , usually 2 month
- description
- Both MRI and PET results will be compared. Lesion location will be defined as "left", "right", "apical", "basal", "midline".
- measure
- Lesion Size
- timeFrame
- Between prostate biopsy and curative treatment decision , usually 2 month
- description
- Both MRI and PET results will be compared, Lesion size will be stated in milimeters.
- measure
- Lymph node involvement
- timeFrame
- Between prostate biopsy and curative treatment decision , usually 2 month
- description
- Both MRI and PET results will be compared. Involvement will be stated as "exist", "non-exist".
Eligibility
Eligibility (as posted)
- Sex
- Male
Show eligibility criteria text
Inclusion Criteria: * diagnosed with prostate cancer * Gleason score 7 or above / 6 with high risk * No other treatment Exclusion Criteria: * treated with radiotherapy * treated with ADT
References
Publications (0)
Data not yet available
No reference posted for this study.